Madrigal Pharmaceuticals :
MDGL
MDGL
Stock Data
$513.72
$3.67 (0.71%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Madrigal Pharmaceuticals Inc is a biopharmaceutical company in the clinical stage, primarily focused on creating treatments for non-alcoholic steatohepatitis (NASH), a liver disease. Their main product in development is resmetirom, aimed at treating NASH through a novel approach as a liver-directed thyroid hormone receptor beta agonist. Currently, resmetirom is undergoing Phase 3 clinical trials. The company operates out of West Conshohocken, Pennsylvania.
All Madrigal Pharmaceuticals Articles
8 Articles